Qiagen (NYSE:QGEN) Releases Q3 Earnings Guidance

Qiagen (NYSE:QGEN) issued an update on its third quarter earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of $0.35-0.36 for the period, compared to the Thomson Reuters consensus estimate of $0.36. Qiagen also updated its Q3 2019 guidance to $0.35-0.36 EPS.

NYSE:QGEN traded down $0.29 during mid-day trading on Monday, hitting $32.06. 1,407,470 shares of the company’s stock traded hands, compared to its average volume of 1,120,962. The firm has a 50 day moving average of $33.75 and a two-hundred day moving average of $37.62. Qiagen has a 12 month low of $31.30 and a 12 month high of $41.55. The firm has a market capitalization of $7.19 billion, a price-to-earnings ratio of 23.93, a price-to-earnings-growth ratio of 2.08 and a beta of 0.85. The company has a current ratio of 1.77, a quick ratio of 1.59 and a debt-to-equity ratio of 0.54.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Wednesday, July 24th. The company reported $0.33 EPS for the quarter, missing the consensus estimate of $0.34 by ($0.01). The firm had revenue of $381.60 million during the quarter, compared to analyst estimates of $386.37 million. Qiagen had a net margin of 12.94% and a return on equity of 12.10%. The company’s revenue was up 1.2% on a year-over-year basis. During the same period last year, the company earned $0.33 EPS. As a group, equities research analysts expect that Qiagen will post 1.41 earnings per share for the current year.

Several equities analysts have commented on QGEN shares. ValuEngine cut Qiagen from a buy rating to a hold rating in a report on Tuesday, August 20th. Berenberg Bank reaffirmed a buy rating on shares of Qiagen in a report on Tuesday, October 1st. Deutsche Bank reaffirmed a buy rating on shares of Qiagen in a report on Friday, July 26th. DZ Bank reaffirmed a neutral rating on shares of Qiagen in a report on Wednesday, July 24th. Finally, Goldman Sachs Group reaffirmed a buy rating on shares of Qiagen in a report on Thursday, August 1st. One analyst has rated the stock with a sell rating, five have given a hold rating and eight have issued a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $41.20.

Qiagen Company Profile

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Further Reading: Backdoor Roth IRA Conversion and Strategy

Earnings History and Estimates for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.